Összefoglaló. A szerzett haemophilia A ritka autoimmun betegség, melyben gátlótest képződik a VIII. véralvadási faktor ellen. Az inhibitor véralvadásra gyakorolt hatása súlyos, életet veszélyeztető vérzéses állapotot idéz elő. A beteg élete a gyors diagnózison múlik: a jellemző klinikai kép mellett a megnyúlt, normálplazmával nem korrigálható aktivált parciális tromboplasztinidő megléte esetén a kórkép alapos gyanúja merül fel. Egy súlyos vérszegénység miatt kórházunkba beutalt nőbeteg esetében a szerzett haemophilia A a felvételt követő napon már diagnosztizálásra került. A vérzés megszüntetésére aktivált protrombinkomplex-koncentrátumot alkalmaztunk, valamint immunszuppresszív terápiát vezettünk be. A kórkép korai felismerése és a megfelelő kezelés azonnali megkezdése a beteg gyógyulását eredményezte. Esetünkkel arra szeretnénk felhívni a figyelmet, hogy a szerzett haemophilia A gyors diagnózisa egyszerű, könnyen hozzáférhető véralvadási paraméter, az aktivált parciális tromboplasztinidő meghatározásán és nem korrigálható megnyúlásának felismerésén múlik. Orv Hetil. 2021; 162(49): 1977–1981.
Summary. Acquired haemophilia A is a rare autoimmune disorder, in which antibodies are formed against coagulation factor VIII. The effect of the inhibitor on blood clotting results in severe, life-threatening bleeding diathesis. The patient’s life depends on the rapid diagnosis: besides the characteristic clinical presentation, a prolonged activated partial thromboplastin time, which is not corrigible with normal plasma, suggests the existence of the disorder. In the case of the female patient who was referred to our hospital due to severe anaemia, acquired haemophilia A was diagnosed rapidly, the day after her admission. We used activated prothrombin complex concentrate to stop the bleeding, and introduced immunosuppressive therapy. The early recognition of the disease and immediate initiation of adequate treatment resulted in the patient’s full recovery. With our case presentation, we would like to draw attention to the fact that the rapid diagnosis of acquired haemophilia A depends on the determination of a simple, easily accessible coagulation parameter, the activated partial thromboplastin time and on the immediate recognition of its incorrigible prolongation. Orv Hetil. 2021; 162(49): 1977–1981.
Pandey Y, Atwal D, Konda M, et al. Acquired hemophilia A. Proc (Bayl Univ Med Cent). 2020; 33: 71–74.
Franchini M, Vaglio S, Marano G, et al. Acquired hemophilia A: a review of recent data and new therapeutic options. Hematology 2017; 22: 514–520.
Franchini M, Lippi G, Favaloro EJ. Acquired inhibitors of coagulation factors: Part II. Semin Thromb Hemost. 2012; 38: 447–453.
Holme PA, Brosstad F, Tjønnfjord GE. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies. Haemophilia 2005; 11: 510–515.
Knoebl P, Marco P, Baudo F, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012; 10: 622–631.
Coppola A, Favaloro EJ, Tufano A, et al. Acquired inhibitors of coagulation factors: Part I. – Acquired hemophilia A. Semin Thromb Hemost. 2012; 38: 433–446.
Collins P, Baudo F, Huth-Kühne A, et al. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Res Notes 2010; 3: 161.
Kruse-Jarres R, Kempton CL, Baudo F, et al. Acquired hemophilia A: updated review of evidence and treatment guidance. Am J Hematol. 2017; 92: 695–705.
Tiede A, Werwitzke S, Scharf RE. Laboratory diagnosis of acquired hemophilia A: limitations, consequences, and challenges. Semin Thromb Hemost. 2014; 40: 803–811.
Cohen AJ, Kessler CM. Acquired inhibitors. Baillieres Clin Haematol. 1996; 9: 331–354.
Franchini M, Zaffanello M, Lippi G. Acquired hemophilia in pediatrics: a systematic review. Pediatr Blood Cancer 2010; 55: 606–611.
Haider MZ, Anwer F. Acquired hemophilia. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL. August 14, 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560494 [accessed: February 13, 2021].
Huth-Kühne A, Baudo F, Collins P, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009; 94: 566–575.
Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost. 2009; 7: 1737–1740.
Pai M, Crowther MA. Neutralization of heparin activity. Handb Exp Pharmacol. 2012; 207: 265–277.
Hoffmann JJ. Polybrene-neutralization of heparin. Am J Clin Pathol. 1982; 78: 424– 425.
Tiede A, Wahler S. The rising incidence of acquired haemophilia A in Germany. Haemophilia 2021; 27: e466–e468. [Epub 2020 Sep 16]
Árokszállási A, Ilonczai P, Rázsó K, et al. Acquired haemophilia: an often overlooked cause of bleeding – experience from a Hungarian tertiary care centre. Blood Coagul Fibrinolysis 2012; 23: 584–589.
Turecek PL, Váradi K, Gritsch H, et al. FEIBA: mode of action. Haemophilia 2004; 10(Suppl 2): 3–9.
Baudo F, Collins P, Huth-Kühne A, et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood 2012; 120: 39–46.
Hedner U. Recombinant factor VIIa (NovoSeven®) as a hemostatic agent. In: Wiestner A, Young NS. (eds.) Seminars in Hematology. W.B. Saunders, Philadelphia, PA, 2001; pp. 43–47.
Leissinger C, Gringeri A, Antmen B, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med. 2011; 365: 1684–1692.
Antunes SV, Tangada S, Stasyshyn O, et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia 2014; 20: 65–72.
Árokszállási A, Rázsó K, Ilonczai P, et al. A decade-long clinical experience on the prophylactic use of activated prothrombin complex concentrate in acquired haemophilia A: a case series from a tertiary care centre. Blood Coagul Fibrinolysis 2018; 29: 282–287.
Dimichele DM. Management of factor VIII inhibitors. Int J Hematol. 2006; 83: 119–125.
Jiang L, Liu Y, Zhang L, et al. Rituximab for treating inhibitors in people with inherited severe hemophilia. Cochrane Database Syst Rev. 2020; 8: CD010810.
Ilonczai P, Schlammadinger A, Oláh Z, et al. Temporarily successful eradication therapy in acquired haemophilia with high inhibitor titer: a case report with a new protocol. Thromb Haemost. 2008; 100: 149–150.